Drug Trial Radar · NCT05630794
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Oct 6, 2025
Primary completion
Jul 1, 2028
Study completion May 1, 2029
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Nov 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this phase I trial is to test the safety and cancer preventive effects of different doses of ONC201 in people with familial adenomatous polyposis (FAP) or a history of multiple polyps. People with familial adenomatous polyposis (FAP) or a history of multiple polyps are at higher than average risk of developing colorectal cancer. ONC201, now known as dordaviprone, is a drug that may stop cancer cells from growing. This drug has been shown in previous studies to cause cancer cell death but not harm normal cells. If successful, this study may help us develop a new option for colorectal cancer prevention.
Conditions
- Colorectal Adenomatous Polyp
- Colorectal Carcinoma
- Familial Adenomatous Polyposis
- Multiple Adenomatous Polyps
Interventions
Biopsy ProcedureProcedure
Undergo biopsy
Biospecimen CollectionProcedure
Undergo collection of blood
ColonoscopyProcedure
Undergo colonoscopy
Dordaviprone HydrochlorideDrug
Given PO
Endoscopic ProcedureProcedure
Undergo lower endoscopic evaluation
Questionnaire AdministrationOther
Ancillary studies
SigmoidoscopyProcedure
Undergo sigmoidoscopy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with unacceptable toxicityTime frame: Up to 35 days post last dose of ONC201
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan · Recruiting
Washington University School of Medicine
St Louis, Missouri · Not yet recruiting
Cleveland Clinic Foundation
Cleveland, Ohio · Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
Rhode Island Hospital
Providence, Rhode Island · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.